Anglo-Japanese JV announces Shingrix submission in Japan

18 April 2017

Japan Vaccine Co, a joint venture of UK pharma major GlaxoSmithKline (LSE: GSK) and Japanese company Daiichi Sankyo (TYO: 4568), have submitted a New Drug Application in Japan seeking approval for the candidate shingles vaccine, Shingrix, for the prevention of herpes zoster (shingles) in people aged 50 years or over.

The regulatory submission for the candidate vaccine is based on a comprehensive Phase III program evaluating its efficacy, safety and immunogenicity in more than 37,000 people in 18 countries, including Japan.

This program showed that by reducing the incidence of shingles, Shingrix also reduced the overall incidence of postherpetic neuralgia, a form of chronic pain associated with shingles.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK